Related coverage linked through entity extraction aliases.
Feb 28, 2026
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Feb 27, 2026
The FDA announced plans to restrict GLP-1 active pharmaceutical ingredients for compounded drugs and combat misleading advertising, following the Trump administration's launch of TrumpRx and ongoing enforcement actions against compounding pharmacies.
Feb 26, 2026
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Feb 26, 2026
The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.
Feb 24, 2026
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
Feb 20, 2026
Private prescriptions for GLP-1 weight-loss drugs in England are concentrated in affluent areas despite higher obesity rates in deprived regions. Online pharmacies face scrutiny for inadequate verification checks when dispensing these medications.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 16, 2026
The FDA approved an oral version of Wegovy in December 2025, providing a pill alternative to injections. Clinical trials showed comparable effectiveness between oral and injectable forms of semaglutide for weight loss.
Feb 16, 2026
DNA methylation-derived Protein EpiScores significantly improved prognostic accuracy for colorectal cancer survival when added to traditional clinical risk factors, raising concordance indices from 0.64 to 0.70 for disease-free survival and 0.70 to 0.75 for overall survival.
Feb 20, 2026
Switzerland-based CRISPR Therapeutics stands to benefit from increased Casgevy sales following partner Vertex Pharmaceuticals' fourth-quarter results, with five additional gene-editing therapies in clinical trials targeting larger patient populations.
Feb 17, 2026
Moderna posted Q4 2025 revenue of $678 million, beating analyst estimates despite a 29.8% year-over-year decline. The company reduced operating expenses by 31% while facing FDA refusal to file its flu vaccine application.
Feb 19, 2026
A randomized trial found that men with prostate cancer treated with the GnRH agonist leuprolide experienced significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix, suggesting a biological mechanism for cardiovascular risk differences between ADT drug pathways.
Feb 18, 2026
CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.
Feb 18, 2026
Novartis has entered a research and licensing agreement worth up to $1.8 billion with Unnatural Products to develop oral peptide medicines targeting cardiovascular disease using macrocyclic peptide technology.
Feb 18, 2026
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
Feb 17, 2026
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Feb 16, 2026
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
Feb 16, 2026
Researchers used a machine-learning tool to analyze 500,000 UK Biobank participants, providing the first population-scale evidence that insulin resistance is a risk factor for 12 types of cancer.
Feb 16, 2026
Genentech's Phase III MAJESTY study showed Gazyva achieved statistically significant complete remission rates versus tacrolimus in primary membranous nephropathy, a chronic autoimmune kidney disease affecting over 96,000 people in the U.S.
Feb 16, 2026
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
